A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 524.75
GOOG 526.94
MSFT 39.69
BAC 16.37
FB 61.36

Recently Added

VJET 17.19
STLY 2.97
GUID 9.21
ICFI 39.15
NCIT 10.38

Gaining Speed

VJET 17.19
GLOG 27.43
GOLD 79.55
ABX 17.81
GG 24.71

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!